Impact of 6 months of treatment with intragastric balloon on body fat and quality of life in obese individuals with metabolic syndrome
- PMID: 29065923
- PMCID: PMC5655862
- DOI: 10.1186/s12955-017-0790-x
Impact of 6 months of treatment with intragastric balloon on body fat and quality of life in obese individuals with metabolic syndrome
Abstract
Background: Obesity is a worldwide public health issue with a negative impact on quality of life. Different weight loss interventions have demonstrated improvements in quality of life. The aim of this study was to investigate the effect of 6 months of treatment with an intragastric balloon (IGB) on health-related quality of life (HRQOL) and its relation to changes in body fat in obese individuals with metabolic syndrome (MS).
Methods: Fifty obese patients with MS aged 18-50 were selected for treatment with IGB for 6 months. Body fat was assessed with anthropometric measures and dual-energy X-ray absorptiometry (DXA) at baseline and after removal of the IGB. HRQOL was evaluated with the short form of the World Health Organization Quality of Life (WHOQOL-BREF) at baseline and soon after removal of the IGB.
Results: Thirty-nine patients completed the study. After 6 months, there was a significant improvement in quality of life (p = 0.0009) and health (p < 0.0001) perceptions, and in the Physical (p = 0.001), Psychological (p = 0.031), and Environmental domains (p = 0.0071). Anthropometric measures and total fat determined by DXA were directly and significantly related to an improvement in general aspects of quality of life. The decrease in the percentage of total fat was the parameter that better correlated with improvements in quality of life perception after regression (p = 0.032).
Conclusions: In obese individuals with MS, weight loss parameters were associated with short-term improvements in HRQOL after 6 months of treatment with IGB. However, only total fat was independently related to HRQOL perception.
Trial registration: ClinicalTrials.gov NCT01598233 .
Keywords: Body composition; Health-related quality of life; Intragastric balloon; Obesity.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the State Institute of Diabetes and Endocrinology of Rio de Janeiro and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from each participant included in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Similar articles
-
Psychological Aspects of Treatment with Intragastric Balloon for Management of Obesity: A Systematic Review of the Literature.Obes Facts. 2022;15(1):1-18. doi: 10.1159/000518200. Epub 2021 Nov 23. Obes Facts. 2022. PMID: 34818229 Free PMC article.
-
Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months.Obes Surg. 2019 Mar;29(3):843-850. doi: 10.1007/s11695-018-3609-x. Obes Surg. 2019. PMID: 30536199
-
Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome.Diabetol Metab Syndr. 2016 Dec 19;8:81. doi: 10.1186/s13098-016-0197-6. eCollection 2016. Diabetol Metab Syndr. 2016. PMID: 28031749 Free PMC article.
-
Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome.Obes Surg. 2014 Feb;24(2):232-40. doi: 10.1007/s11695-013-1061-5. Obes Surg. 2014. PMID: 23949905 Clinical Trial.
-
Intragastric Balloon Treatment for Obesity: Review of Recent Studies.Adv Ther. 2017 Aug;34(8):1859-1875. doi: 10.1007/s12325-017-0562-3. Epub 2017 Jul 13. Adv Ther. 2017. PMID: 28707286 Review.
Cited by
-
[Intragastric balloon for weight reduction: rationale, benefits, risks and indications].Nan Fang Yi Ke Da Xue Xue Bao. 2020 Oct 30;40(10):1525-1529. doi: 10.12122/j.issn.1673-4254.2020.10.21. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 33118505 Free PMC article. Chinese.
-
In vivo medical imaging for assessing geroprotective interventions in humans.Geroscience. 2025 Jun;47(3):2721-2737. doi: 10.1007/s11357-025-01514-y. Epub 2025 Feb 6. Geroscience. 2025. PMID: 39913033 Free PMC article. Review.
-
Psychological Aspects of Treatment with Intragastric Balloon for Management of Obesity: A Systematic Review of the Literature.Obes Facts. 2022;15(1):1-18. doi: 10.1159/000518200. Epub 2021 Nov 23. Obes Facts. 2022. PMID: 34818229 Free PMC article.
-
Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months.Obes Surg. 2019 Mar;29(3):843-850. doi: 10.1007/s11695-018-3609-x. Obes Surg. 2019. PMID: 30536199
-
Real Life Changes in Physical Activity Due to Intragastric Balloon Therapy and Their Relationship to Improving Cognitive Functions: Preliminary Findings.Obes Surg. 2020 Jul;30(7):2821-2825. doi: 10.1007/s11695-020-04440-4. Obes Surg. 2020. PMID: 32020503 Free PMC article.
References
-
- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384:766–781. doi: 10.1016/S0140-6736(14)60460-8. - DOI - PMC - PubMed
-
- Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Maneg Care. 2016;22(7 Suppl):s176–s185. - PubMed
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical